| Year |
Citation |
Score |
| 2023 |
Aly AE, Sun T, Zhang Y, Li Z, Kyada M, Ma Q, Padegimas L, Sesenoglu-Laird O, Cooper MJ, McDannold NJ, Waszczak BL. Focused ultrasound enhances transgene expression of intranasal hGDNF DNA nanoparticles in the sonicated brain regions. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 37127076 DOI: 10.1016/j.jconrel.2023.04.041 |
0.456 |
|
| 2018 |
Aly AE, Harmon B, Padegimas L, Sesenoglu-Laird O, Cooper MJ, Yurek DM, Waszczak BL. Intranasal delivery of hGDNF plasmid DNA nanoparticles results in long-term and widespread transfection of perivascular cells in rat brain. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 30472323 DOI: 10.1016/J.Nano.2018.11.006 |
0.704 |
|
| 2018 |
Cai X, Qiao J, Knox T, Iriah S, Kulkarni P, Madularu D, Morrison T, Waszczak B, Hartner JC, Ferris CF. In search of early neuroradiological biomarkers for Parkinson's Disease: Alterations in resting state functional connectivity and gray matter microarchitecture in PINK1 -/- rats. Brain Research. PMID 30389398 DOI: 10.1016/J.Brainres.2018.10.033 |
0.428 |
|
| 2018 |
Aly AE, Harmon BT, Padegimas L, Sesenoglu-Laird O, Cooper MJ, Waszczak BL. Intranasal Delivery of pGDNF DNA Nanoparticles Provides Neuroprotection in the Rat 6-Hydroxydopamine Model of Parkinson's Disease. Molecular Neurobiology. PMID 29779176 DOI: 10.1007/S12035-018-1109-6 |
0.708 |
|
| 2015 |
Aly AE, Waszczak BL. Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier. Expert Opinion On Drug Delivery. 1-19. PMID 26289676 DOI: 10.1517/17425247.2015.1069815 |
0.445 |
|
| 2015 |
Bender TS, Migliore MM, Campbell RB, John Gatley S, Waszczak BL. Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats. Neuroscience. 303: 569-576. PMID 26166725 DOI: 10.1016/J.Neuroscience.2015.07.016 |
0.672 |
|
| 2014 |
Migliore MM, Ortiz R, Dye S, Campbell RB, Amiji MM, Waszczak BL. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease. Neuroscience. 274: 11-23. PMID 24845869 DOI: 10.1016/J.Neuroscience.2014.05.019 |
0.654 |
|
| 2014 |
Harmon BT, Aly AE, Padegimas L, Sesenoglu-Laird O, Cooper MJ, Waszczak BL. Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain. Gene Therapy. 21: 514-21. PMID 24670994 DOI: 10.1038/Gt.2014.28 |
0.7 |
|
| 2010 |
Migliore MM, Vyas TK, Campbell RB, Amiji MM, Waszczak BL. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. Journal of Pharmaceutical Sciences. 99: 1745-61. PMID 19774660 DOI: 10.1002/Jps.21939 |
0.625 |
|
| 2007 |
Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, Wiard RP, Feldman PL, Collins H, Waszczak BL, Tilbrook GS. CNS 7056: a novel ultra-short-acting Benzodiazepine. Anesthesiology. 107: 60-6. PMID 17585216 DOI: 10.1097/01.Anes.0000267503.85085.C0 |
0.393 |
|
| 2004 |
Zahr NM, Martin LP, Waszczak BL. Subthalamic nucleus lesions alter basal and dopamine agonist stimulated electrophysiological output from the rat basal ganglia. Synapse (New York, N.Y.). 54: 119-28. PMID 15352137 DOI: 10.1002/Syn.20064 |
0.414 |
|
| 2002 |
Waszczak BL, Martin LP, Finlay HE, Zahr N, Stellar JR. Effects of individual and concurrent stimulation of striatal D1 and D2 dopamine receptors on electrophysiological and behavioral output from rat basal ganglia. The Journal of Pharmacology and Experimental Therapeutics. 300: 850-61. PMID 11861790 DOI: 10.1124/Jpet.300.3.850 |
0.35 |
|
| 2001 |
Waszczak BL, Martin L, Boucher N, Zahr N, Sikes RW, Stellar JR. Electrophysiological and behavioral output of the rat basal ganglia after intrastriatal infusion of d-amphetamine: lack of support for the basal ganglia model. Brain Research. 920: 170-82. PMID 11716823 DOI: 10.1016/S0006-8993(01)03059-1 |
0.401 |
|
| 2000 |
Hinerth MA, Collins HA, Baniecki M, Hanson RN, Waszczak BL. Novel in vivo electrophysiological assay for the effects of cocaine and putative "cocaine antagonists" on dopamine transporter activity of substantia nigra and ventral tegmental area dopamine neurons. Synapse (New York, N.Y.). 38: 305-12. PMID 11020233 DOI: 10.1002/1098-2396(20001201)38:3<305::Aid-Syn9>3.0.Co;2-U |
0.34 |
|
| 1998 |
Waszczak BL, Martin LP, Greif GJ, Freedman JE. Expression of a dopamine D2 receptor-activated K+ channel on identified striatopallidal and striatonigral neurons. Proceedings of the National Academy of Sciences of the United States of America. 95: 11440-4. PMID 9736755 DOI: 10.1073/Pnas.95.19.11440 |
0.354 |
|
| 1996 |
Martin LP, Waszczak BL. Dopamine D2, receptor-mediated modulation of the GABAergic inhibition of substantia nigra pars reticulata neurons. Brain Research. 729: 156-69. PMID 8876984 DOI: 10.1016/0006-8993(96)00226-0 |
0.378 |
|
| 1994 |
Freedman JE, Waszczak BL, Cox RF, Liu JC, Greif GJ. The dopamine D3 receptor and 7-OH-DPAT. Trends in Pharmacological Sciences. 15: 173-4. PMID 7916508 DOI: 10.1016/0165-6147(94)90138-4 |
0.311 |
|
| 1994 |
Martin LP, Waszczak BL. D1 agonist-induced excitation of substantia nigra pars reticulata neurons: mediation by D1 receptors on striatonigral terminals via a pertussis toxin-sensitive coupling pathway. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 14: 4494-506. PMID 7913124 DOI: 10.1523/Jneurosci.14-07-04494.1994 |
0.365 |
|
| 1994 |
Liu JC, Cox RF, Greif GJ, Freedman JE, Waszczak BL. The putative dopamine D3 receptor agonist 7-OH-DPAT: lack of mesolimbic selectivity. European Journal of Pharmacology. 264: 269-78. PMID 7698165 DOI: 10.1016/0014-2999(94)00477-3 |
0.382 |
|
| 1993 |
Cox RF, Meller E, Waszczak BL. Electrophysiological evidence for a large receptor reserve for inhibition of dorsal raphe neuronal firing by 5-HT1A agonists. Synapse (New York, N.Y.). 14: 297-304. PMID 8248853 DOI: 10.1002/Syn.890140407 |
0.381 |
|
| 1993 |
Cox RF, Waszczak BL. Inhibition of substantia nigra dopamine cell firing by R(-)-N-n-propylnorapomorphine: electrophysiological and autoradiographic studies after regional inactivation of dopamine receptors by microinjection of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Brain Research. 613: 32-42. PMID 8102308 DOI: 10.1016/0006-8993(93)90450-2 |
0.373 |
|
| 1991 |
Cox RF, Waszczak BL. Autoradiography of dopamine D2 receptors using [3H]YM-09151-2. European Journal of Pharmacology. 199: 103-6. PMID 1680055 DOI: 10.1016/0014-2999(91)90642-4 |
0.35 |
|
| 1990 |
Martin LP, Cox RF, Waszczak BL. Efficacy and potency comparisons among aporphine enantiomers: effects on dopamine neurons in substantia nigra of rat. Neuropharmacology. 29: 135-43. PMID 2184376 DOI: 10.1016/0028-3908(90)90053-T |
0.379 |
|
| 1990 |
Waszczak BL. Differential effects of D1 and D2 dopamine receptor agonists on substantia nigra pars reticulata neurons. Brain Research. 513: 125-35. PMID 2140951 DOI: 10.1016/0006-8993(90)91098-2 |
0.381 |
|
| 1990 |
Jackson DM, Martin LP, Larsson LG, Cox RF, Waszczak BL, Ross SB. Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine. Naunyn-Schmiedeberg's Archives of Pharmacology. 342: 290-9. PMID 2126347 DOI: 10.1007/Bf00169440 |
0.356 |
|
| 1990 |
Cox RF, Waszczak BL. Irreversible receptor inactivation reveals differences in dopamine receptor reserve between A9 and A10 dopamine systems: an electrophysiological analysis. Brain Research. 534: 273-82. PMID 1981482 DOI: 10.1016/0006-8993(90)90139-3 |
0.362 |
|
| 1988 |
Waszczak BL, Applegate CD, Burchfiel JL. Kindling does not cause persistent changes in firing rates or transmitter sensitivities of substantia nigra pars reticulata neurons. Brain Research. 455: 115-22. PMID 2901283 DOI: 10.1016/0006-8993(88)90120-5 |
0.371 |
|
| 1987 |
Toussi HR, Schatz RA, Waszczak BL. Suppression of methionine sulfoximine seizures by intranigral gamma-vinyl GABA injection. European Journal of Pharmacology. 137: 261-4. PMID 3609144 DOI: 10.1016/0014-2999(87)90232-9 |
0.305 |
|
| 1984 |
Waszczak BL, Lee EK, Ferraro T, Hare TA, Walters JR. Single unit responses of substantia nigra pars reticulata neurons to apomorphine: effects of striatal lesions and anesthesia. Brain Research. 306: 307-18. PMID 6466980 DOI: 10.1016/0006-8993(84)90380-9 |
0.409 |
|
| 1984 |
Waszczak BL, Lee EK, Tamminga CA, Walters JR. Effect of dopamine system activation on substantia nigra pars reticulata output neurons: variable single-unit responses in normal rats and inhibition in 6-hydroxydopamine-lesioned rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 4: 2369-75. PMID 6434704 DOI: 10.1523/Jneurosci.04-09-02369.1984 |
0.338 |
|
| 1983 |
Waszczak BL. Diazepam potentiates GABA-, but not adenosine-mediated, inhibition of neurons of the nigral pars reticulata. Neuropharmacology. 22: 953-9. PMID 6621825 DOI: 10.1016/0028-3908(83)90211-3 |
0.335 |
|
| 1982 |
Ross RJ, Waszczak BL, Lee EK, Walters JR. Effects of benzodiazepines on single unit activity in the substantia nigra pars reticulata. Life Sciences. 31: 1025-35. PMID 6813614 DOI: 10.1016/0024-3205(82)90175-8 |
0.392 |
|
| 1980 |
Waszczak BL, Walters JR. Intravenous GABA agonist administration stimulates firing of A10 dopaminergic neurons. European Journal of Pharmacology. 66: 141-4. PMID 7408962 DOI: 10.1016/0014-2999(80)90308-8 |
0.332 |
|
| 1980 |
Waszczak BL, Hruska RE, Walters JR. GABAergic actions of THIP in vivo and vitro: a comparison with muscimol and GABA. European Journal of Pharmacology. 65: 21-9. PMID 7398775 DOI: 10.1016/0014-2999(80)90204-6 |
0.326 |
|
| 1980 |
Waszczak BL, Eng N, Walters JR. Effects of muscimol and picrotoxin on single unit activity of substantia nigra neurons. Brain Research. 188: 185-97. PMID 7370752 DOI: 10.1016/0006-8993(80)90567-3 |
0.376 |
|
| Show low-probability matches. |